Pharmosa Biopharm Inc. (TPEX: 6875)
Taiwan
· Delayed Price · Currency is TWD 54.30
+0.10 (0.18%)
Jan 21, 2025, 1:30 PM CST
Pharmosa Biopharm Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 |
| Revenue | 50.52 | 314.5 | - | - | - | - | Upgrade
|
| Gross Profit | 13.42 | 314.5 | - | - | - | - | Upgrade
|
| Selling, General & Admin | 52.63 | 40.35 | 29.22 | 18.32 | 12.11 | 10.15 | Upgrade
|
| Research & Development | 283.63 | 276.97 | 242.31 | 240.81 | 175.31 | 128.99 | Upgrade
|
| Operating Expenses | 336.26 | 317.32 | 271.53 | 259.12 | 187.42 | 139.15 | Upgrade
|
| Operating Income | -322.84 | -2.82 | -271.53 | -259.12 | -187.42 | -139.15 | Upgrade
|
| Interest Expense | -3.06 | -2.86 | -0.65 | -1.21 | -3.86 | -2.87 | Upgrade
|
| Interest & Investment Income | 28.4 | 9.53 | 0.5 | 0.1 | 0.04 | 0.03 | Upgrade
|
| Earnings From Equity Investments | 3.62 | 5.5 | 3.93 | 0.66 | 4.63 | -1.4 | Upgrade
|
| Currency Exchange Gain (Loss) | -5.67 | -6.68 | 1.02 | 0.2 | 0.96 | -0.27 | Upgrade
|
| Other Non Operating Income (Expenses) | 6.79 | 5.79 | 0.23 | 2.89 | 3.96 | 0.3 | Upgrade
|
| EBT Excluding Unusual Items | -292.77 | 8.46 | -266.51 | -256.48 | -181.7 | -143.36 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | - | - | 13.73 | Upgrade
|
| Pretax Income | -292.93 | 8.46 | -266.51 | -256.48 | -181.7 | -129.63 | Upgrade
|
| Net Income | -292.93 | 8.46 | -266.51 | -256.48 | -181.7 | -129.63 | Upgrade
|
| Net Income to Common | -292.93 | 8.46 | -266.51 | -256.48 | -181.7 | -129.63 | Upgrade
|
| Shares Outstanding (Basic) | 123 | 113 | 99 | 85 | 48 | 37 | Upgrade
|
| Shares Outstanding (Diluted) | 123 | 113 | 99 | 85 | 48 | 37 | Upgrade
|
| Shares Change (YoY) | 13.07% | 15.09% | 16.02% | 78.34% | 27.94% | 61.72% | Upgrade
|
| EPS (Basic) | -2.37 | 0.07 | -2.70 | -3.02 | -3.82 | -3.48 | Upgrade
|
| EPS (Diluted) | -2.37 | 0.07 | -2.70 | -3.02 | -3.82 | -3.48 | Upgrade
|
| Free Cash Flow | -454.84 | -39.04 | -268.47 | -240.57 | -188.5 | -131.81 | Upgrade
|
| Free Cash Flow Per Share | -3.68 | -0.34 | -2.72 | -2.83 | -3.96 | -3.54 | Upgrade
|
| Gross Margin | 26.57% | 100.00% | - | - | - | - | Upgrade
|
| Operating Margin | -639.02% | -0.90% | - | - | - | - | Upgrade
|
| Profit Margin | -579.83% | 2.69% | - | - | - | - | Upgrade
|
| Free Cash Flow Margin | -900.31% | -12.41% | - | - | - | - | Upgrade
|
| EBITDA | -312.67 | 2.99 | -266.24 | -254.73 | -184.2 | -136.43 | Upgrade
|
| EBITDA Margin | - | 0.95% | - | - | - | - | Upgrade
|
| D&A For EBITDA | 10.17 | 5.81 | 5.3 | 4.39 | 3.22 | 2.71 | Upgrade
|
| EBIT | -322.84 | -2.82 | -271.53 | -259.12 | -187.42 | -139.15 | Upgrade
|
| EBIT Margin | - | -0.90% | - | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.